Combining antiangiogenics to overcome resistance: rationale and clinical experience
about
Molecularly targeted drugs for metastatic colorectal cancerProfile of trebananib (AMG386) and its potential in the treatment of ovarian cancerProlonged survival after sequential multimodal treatment in metastatic renal cell carcinoma: two case reports and a review of the literature.Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkersIn vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer TherapyZiv-aflibercept in metastatic colorectal cancerT cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105)A network model for angiogenesis in ovarian cancer.A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivDrug compound characterization by mass spectrometry imaging in cancer tissue.New ways to successfully target tumor vasculature in ovarian cancer.Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis.Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model.Recurrent oral cancer: current and emerging therapeutic approaches.Tumor angiogenesis phenotyping by nanoparticle-facilitated magnetic resonance and near-infrared fluorescence molecular imaging.Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and CilengitideBeyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy.Ramucirumab for the treatment of gastroesophageal cancers.New developments in the treatment of ovarian cancer--future perspectives.A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.Temsirolimus: a safety and efficacy review.Therapeutic targeting of VEGF in the treatment of glioblastoma.Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies.Understanding and targeting resistance to anti-angiogenic therapies.Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma.Anti-angiogenic agent ramucirumab: meaningful or marginal?Vandetanib as a potential treatment for breast cancer.Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.Mechanism of tumour vascularization in experimental lung metastases.Direct effect of bevacizumab on glioblastoma cell lines in vitro.Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.Eph/ephrin sytem: In the quest of novel anti-angiogenic therapies.Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.
P2860
Q26828735-A6613937-3CA6-43FD-B5F4-A293EF3A1BFBQ26991997-9F6C3266-D9C0-4EC3-B0F6-9E751DCD9DB6Q30565687-951C7369-106F-4988-9CEB-B7AE5BF4A552Q33415397-46654F66-3C72-4596-BECC-2BBB6E099192Q33738607-31FE9134-2D04-4ED4-B1B8-39A65856D4AFQ33770680-65956424-3089-42B2-BDD3-1DE5773C12EBQ33859472-7EE2C18C-3481-4F3B-9D10-30CBEB9E3C01Q34658579-F65D9400-F548-42F2-BE37-B30CFAD6D61CQ34893030-64756700-0E81-4CA7-BEFD-282BCEB0A0ADQ35039240-3E193862-6080-4745-B94D-FDF87CD550ADQ35158941-222A5AD6-26CA-49A9-A10A-F8C1CF2824D2Q35534413-DD74092B-2BBE-42EC-9295-5AF8FAC11A8EQ35695946-587ED399-24C4-44E8-809D-C462C9642C5BQ35704471-9C6E9174-0AAA-45CE-9581-ECD36A1CCA95Q35928220-28DAE0F9-C92B-45E1-A120-B7C7D42A77E9Q36086593-ED6C8430-3CB8-4A22-A780-469712760267Q36279079-0C3AA0E0-05B4-47B8-9747-464D5BE03882Q36283038-B4CED86B-548F-4740-A151-C279D23A92D9Q36343788-A2C30DCC-1A77-49CD-9431-957D8917BC05Q36368035-DDBEAD24-B615-4213-B4F5-070EB870EF06Q36881812-625BD930-B664-4127-B329-95A6D13C082DQ37211153-6278E1A0-1412-42E9-9A62-A3A676FB1D35Q37332487-0D13EEB0-693E-4B69-8D60-8CD5DFBB5B6CQ37513843-F8465FE6-895B-4CE6-9AD3-43FF2D9B907CQ38031941-90CA100A-2213-4F6C-B84B-DE4CD10A49B7Q38033241-F563991A-3A6B-46BA-ADB4-CB9090CF093EQ38046514-21E9DD1F-FFDA-4749-A870-B8FCFAB81F78Q38066416-18DBA2BC-5F0B-452E-BCDD-9797E8099E96Q38133568-95229D4E-9C16-4951-96D9-3F20FF24DABEQ38155510-42F4FDA4-FAED-45A3-AF8E-8B5F8EAE92A9Q38194159-4B4F8651-BC4C-4B3D-9D87-C9398066EB92Q38236623-64B781D0-7453-4241-BD9E-41113EAD20ADQ38757723-57B2D98E-DAE3-4D40-82C3-0E43E0B41501Q38947459-F1C96F65-00B3-4683-BA7A-8D84B8188514Q38967004-4AE564CD-E8D4-49B3-A419-FDDCAAF00C58Q41431404-6C80901B-75BA-488B-8510-4F620B1B736FQ42121734-FF48CC13-77C0-491F-8A5C-B479C87F8984Q48369496-56A0EDB1-9C88-4F19-839D-2C76DE59A928
P2860
Combining antiangiogenics to overcome resistance: rationale and clinical experience
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Combining antiangiogenics to overcome resistance: rationale and clinical experience
@ast
Combining antiangiogenics to overcome resistance: rationale and clinical experience
@en
Combining antiangiogenics to overcome resistance: rationale and clinical experience
@nl
type
label
Combining antiangiogenics to overcome resistance: rationale and clinical experience
@ast
Combining antiangiogenics to overcome resistance: rationale and clinical experience
@en
Combining antiangiogenics to overcome resistance: rationale and clinical experience
@nl
prefLabel
Combining antiangiogenics to overcome resistance: rationale and clinical experience
@ast
Combining antiangiogenics to overcome resistance: rationale and clinical experience
@en
Combining antiangiogenics to overcome resistance: rationale and clinical experience
@nl
P2093
P3181
P1476
Combining antiangiogenics to overcome resistance: rationale and clinical experience
@en
P2093
L. R. Molife
S. B. Kaye
V. Moreno Garcia
P304
P3181
P356
10.1158/1078-0432.CCR-11-1275
P407
P577
2012-07-15T00:00:00Z